Inventory of indications and adverse reactions of domestic immunotherapy drug camrelizumab!

Camrelizumab is a PD-1 immune checkpoint inhibitor independently developed by the local company Hengrui Medicine
.
As a domestic immunotherapy drug, camrelizumab was launched earlier, and it is the third domestic PD-1 anticancer drug after toripalizumab and sintilimab.
It has been widely used in clinical practice in recent years
.

Camrelizumab is a PD-1 immune checkpoint inhibitor independently developed by the local company Hengrui Medicine
.
As a domestic immunotherapy drug, camrelizumab was launched earlier, and it is the third domestic PD-1 anticancer drug after toripalizumab and sintilimab.
It has been widely used in clinical practice in recent years
.
immunity

 

With the release of a large number of clinical trial data, the range of indications of camrelizumab in the clinic has gradually increased
.
At present , camrelizumab has been approved for 8 indications, covering 5 types of malignant tumors
.
Today, we will take stock of the approved indications, adverse reactions and treatment measures of camrelizumab
.

With the release of a large number of clinical trial data, the range of indications of camrelizumab in the clinic has gradually increased
.
At present , camrelizumab has been approved for 8 indications, covering 5 types of malignant tumors
.
Today, we will take stock of the approved indications, adverse reactions and treatment measures of camrelizumab
.
Camrelizumab has 8 approved indications, covering 5 types of malignant tumors
.

 

 

1.
Eight indications for camrelizumab

1.
Eight major indications of camrelizumab 1.
Eight major indications of camrelizumab

 

 

 

 

2.
Adverse reactions and treatment of camrelizumab

2.
Adverse reactions and treatment of camrelizumab 2.
Adverse reactions of camrelizumab and treatment of camrelizumab

 

1.
Reactive Cutaneous Capillary Hyperplasia (RCCEP)

1.
Reactive Cutaneous Capillary Hyperplasia 1.
Reactive Cutaneous Capillary Hyperplasia Vascular (RCCEP) (RCCEP)

 

  Occurrence site Occurrence site : mainly occurs in the human body surface skin, mostly found in the head, face and trunk; most of them are isolated and scattered
.
Gross classification : According to the appearance, it is roughly divided into red nevus type, pearl type, mulberry type, patch type, tumor-like type; red nevus type and pearl type are the most common
.

The law of occurrence: The law of occurrence:
 

 

RCCEP Grading Criteria: RCCEP Grading Criteria: * No cases of visceral hemorrhage and grade 4-5 RCCEP have been seen so far .

Hierarchical Management of RCCEP: Hierarchical Management of RCCEP : Management Notes : 
 

• Most RCCEPs can be observed or managed symptomatically without specific treatment

  
  

• RCCEP is not sensitive to hormones.

  
  

• Skin infections should be actively treated with topical or systemic antibiotics as appropriate

  
  

Most RCCEPs can be observed or managed symptomatically without specific treatment

Most RCCEPs can be observed or managed symptomatically without specific treatment

Most RCCEPs can be observed or managed symptomatically without specific treatment

RCCEP is not sensitive to hormones.

RCCEP is not sensitive to hormones.

Skin infections should be actively treated with topical or systemic antibiotics as appropriate

Skin infections should be actively treated with topical or systemic antibiotics as appropriate

2.

2.

leave a message here